Literature DB >> 10809910

Incidence of Guillain-Barré syndrome in Sweden 1996.

Q Cheng1, G X Jiang, S Fredrikson, H Link, J De Pedro-Cuesta.   

Abstract

We describe the incidence of Guillain-Barré syndrome (GBS) in Sweden in 1996. Information of incident GBS patients was mainly collected by a multicentre network of 18 neurologists prospectively monitoring a general population with 4.48 million inhabitants across the country and complemented with data from the national hospital in-patient registry. GBS diagnoses for all patients were validated by neurologists. While 53 patients with GBS were identified by the network neurologists from the study population, the other 20 GBS patients were recognized after carefully reviewing the registered data. There were 44 (60%) male patients and 29 (40%) female patients and the mean age at onset for all patients was 48.6 (SD 24.3) years. The GBS incidence, age-adjusted to the European standard population, was 1.51 (95% CI 1.18-1.90) per 100 000 person-years in 1996, higher in males and increased with age. When compared with selected studies, the GBS incidence in Sweden is moderately high, and the variation of GBS incidence in Europe seems to be small.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10809910

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  10 in total

1.  Pathogenesis and treatment of immune-mediated neuropathies.

Authors:  Helmar C Lehmann; Gerd Meyer Zu Horste; Bernd C Kieseier; Hans-Peter Hartung
Journal:  Ther Adv Neurol Disord       Date:  2009-07       Impact factor: 6.570

Review 2.  Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis.

Authors:  James J Sejvar; Andrew L Baughman; Matthew Wise; Oliver W Morgan
Journal:  Neuroepidemiology       Date:  2011-03-21       Impact factor: 3.282

Review 3.  Epidemiology of neuroimmunological diseases.

Authors:  Peter Flachenecker
Journal:  J Neurol       Date:  2006-09       Impact factor: 4.849

Review 4.  [Guillain-Barré syndrome after exposure to influenza].

Authors:  H-P Hartung; B Keller-Stanislawski; R A Hughes; H C Lehmann
Journal:  Nervenarzt       Date:  2012-06       Impact factor: 1.214

5.  Declining Guillain-Barré syndrome after campylobacteriosis control, New Zealand, 1988-2010.

Authors:  Michael G Baker; Amanda Kvalsvig; Jane Zhang; Rob Lake; Ann Sears; Nick Wilson
Journal:  Emerg Infect Dis       Date:  2012-02       Impact factor: 6.883

6.  Comparison of intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated children with Guillain Barré syndrome: a randomized study.

Authors:  Mohammed A El-Bayoumi; Ahmed M El-Refaey; Alaa M Abdelkader; Mohamed M A El-Assmy; Angi A Alwakeel; Hanem M El-Tahan
Journal:  Crit Care       Date:  2011-07-11       Impact factor: 9.097

7.  Intravenous immunoglobulin vs plasma exchange in treatment of mechanically ventilated adults with Guillain-Barré syndrome.

Authors:  Boubaker Charra; Abdelhamid Hachimi; Abdellatif Benslama; Said Motaouakkil
Journal:  Pan Afr Med J       Date:  2014-05-09

8.  Epidemiology of Guillain-Barré syndrome in Finland 2004-2014.

Authors:  Jussi O T Sipilä; Merja Soilu-Hänninen; Jori O Ruuskanen; Päivi Rautava; Ville Kytö
Journal:  J Peripher Nerv Syst       Date:  2017-11-15       Impact factor: 3.494

9.  Incidence, Disability, and Mortality in Patients With Guillain-Barré Syndrome in Korea: A Nationwide Population-Based Study.

Authors:  Sang-Wook Yi; Jung Hwan Lee; Ji-Man Hong; Young-Chul Choi; Hyung Jun Park
Journal:  J Clin Neurol       Date:  2022-01       Impact factor: 3.077

10.  A Bayesian Network to Predict the Risk of Post Influenza Vaccination Guillain-Barré Syndrome: Development and Validation Study.

Authors:  Yun Huang; Chongliang Luo; Ying Jiang; Jingcheng Du; Cui Tao; Yong Chen; Yuantao Hao
Journal:  JMIR Public Health Surveill       Date:  2022-03-25
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.